SILO PHARMA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
SILO PHARMA, INC. (SILO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$846.19K.
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$768.92K.
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$856.03K.
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$6.70M.
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$7.84M, a 612.59% decline from fiscal 2022.
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $1.53M, a 82.43% decline from fiscal 2021.
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $8.71M, a 756.61% increase from fiscal 2020.
- SILO PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $1.02M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.47M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$846.19K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $842.90K POS AM · filed 2026-04-14 | |||
| 2025-09-30 | $11.83K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $427.87K 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$768.92K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $381.49K POS AM · filed 2026-04-14 | |||
| 2024-09-30 | $1.34M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $981.99K 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | -$856.03K 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$7.84M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | -$11.17M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$11.21M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$6.70M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $1.53M 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $2.42M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$1.10M 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | -$769.16K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $8.71M 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $9.13M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $3.02M 10-Q · filed 2022-08-01 | |||
| 2021-03-31 | $3.51M 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $1.02M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $1.53M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $1.81M 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | -$102.61K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | -$224.93K 10-K/A · filed 2021-05-17 | |||
| 2019-09-30 | -$312.12K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$259.71K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |